Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan With Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases (TARGET-TNBC)
Latest Information Update: 25 Feb 2025
Price :
$35 *
At a glance
- Drugs Sacituzumab govitecan (Primary) ; Zimberelimab (Primary)
- Indications Brain metastases; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TARGET-TNBC
- 14 Nov 2024 Status changed from not yet recruiting to recruiting.
- 29 Oct 2024 Planned initiation date changed from 30 Sep 2024 to 29 Oct 2024.
- 03 Sep 2024 Planned initiation date changed from 1 Oct 2024 to 30 Sep 2024.